<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="184">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on August 12, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04383587</url>
  </required_header>
  <id_info>
    <org_study_id>20-004054</org_study_id>
    <nct_id>NCT04383587</nct_id>
  </id_info>
  <brief_title>Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers</brief_title>
  <official_title>Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify healthcare workers with SARS CoV 2 antibodies who&#xD;
      have not been previously diagnosed and are presumed COVID-19 negative, then determine the&#xD;
      level of immunity in this population which could inform further decisions about widespread&#xD;
      antibody testing in a healthcare worker population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enrolled participants will complete a survey gauging their level of confidence they will be&#xD;
      antibody positive. Participants will then complete serologic testing for SARS CoV 2 IgG&#xD;
      antibodies. The study will characterize the prevalence of antibody positivity in this&#xD;
      population and assess whether there is a correlation between a pre-test confidence level&#xD;
      using a Likert scale and actual antibody positivity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 6, 2020</start_date>
  <completion_date type="Actual">July 31, 2020</completion_date>
  <primary_completion_date type="Actual">July 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With COVID-19 Antibodies</measure>
    <time_frame>1 month</time_frame>
    <description>Presence of IgG antibodies detected</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ability to Predict Immune Status/Antibody Positivity</measure>
    <time_frame>Single point in time prior to COVID-19 Antibody testing</time_frame>
    <description>Survey of participants to gauge their confidence they will be antibody positive</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>SARS-CoV 2</condition>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Serologic Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Enrolled participants will have COVID19 IgG antibody testing performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Serologic testing</intervention_name>
    <description>COVID19 IgG antibody testing to be performed</description>
    <arm_group_label>Serologic Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 18 years old.&#xD;
&#xD;
          -  Mayo Clinic employee in procedural and surgical area.&#xD;
&#xD;
          -  Suspected COVID-19 exposure.&#xD;
&#xD;
          -  Completed PCR test twice with negative results.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Refusal to participate in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Parkulo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>April 2022</verification_date>
  <study_first_submitted>May 7, 2020</study_first_submitted>
  <study_first_submitted_qc>May 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <results_first_submitted>February 23, 2022</results_first_submitted>
  <results_first_submitted_qc>April 11, 2022</results_first_submitted_qc>
  <results_first_posted type="Actual">April 13, 2022</results_first_posted>
  <last_update_submitted>April 11, 2022</last_update_submitted>
  <last_update_submitted_qc>April 11, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Mark A. Parkulo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 17, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT04383587/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>394 invited to participate. 300 elected to participate. 292 completed study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Serologic Arm</title>
          <description>Enrolled participants will have COVID19 IgG antibody testing performed.&#xD;
Serologic testing: COVID19 IgG antibody testing performed</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="300"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="292"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Serology Group</title>
          <description>Group of participants completing COVID Serologic antibody testing</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="292"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="292"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="284"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="292"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43" lower_limit="18" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="292"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="174"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="292"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With COVID-19 Antibodies</title>
        <description>Presence of IgG antibodies detected</description>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Serologic Arm</title>
            <description>Enrolled participants will have COVID19 IgG antibody testing performed.&#xD;
Serologic testing: COVID19 IgG antibody testing performed</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With COVID-19 Antibodies</title>
          <description>Presence of IgG antibodies detected</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Positive Antibodies</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Negative Antibodies</title>
                  <measurement_list>
                    <measurement group_id="O1" value="284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Participants were grouped by age (18-35 vs. 36-50 vs. 51-65 vs. &gt;65), Sex at birth (Female vs. Male). and Occupational Role (Technician vs Anesthesiologist vs Advanced Practice Provider vs. Attendant Aide vs. CRNA vs. OR nurse vs Perfusionist vs Surgeon).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.18</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ability to Predict Immune Status/Antibody Positivity</title>
        <description>Survey of participants to gauge their confidence they will be antibody positive</description>
        <time_frame>Single point in time prior to COVID-19 Antibody testing</time_frame>
        <population>Of 292 participants completing the study, 27 responded in a survey (prior to antibody testing) that they had a high confidence (8 or greater on a Likert Scale from 0-10) that they had been previously infected with SARS CoV-2 and would test COVID-19 antibody positive. Antibody results from those 27 participants are listed below.</population>
        <group_list>
          <group group_id="O1">
            <title>High Confidence of Previous Infection</title>
            <description>Participants who indicated in a survey prior to antibody testing that they had a high confidence of previous infection or immunity that would be demonstrated by antibody positivity</description>
          </group>
        </group_list>
        <measure>
          <title>Ability to Predict Immune Status/Antibody Positivity</title>
          <description>Survey of participants to gauge their confidence they will be antibody positive</description>
          <population>Of 292 participants completing the study, 27 responded in a survey (prior to antibody testing) that they had a high confidence (8 or greater on a Likert Scale from 0-10) that they had been previously infected with SARS CoV-2 and would test COVID-19 antibody positive. Antibody results from those 27 participants are listed below.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Antibody negative</title>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Antibody positive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants were instructed to contact investigators if they developed any adverse events within 1 week of blood draw.</time_frame>
      <desc>Bleeding, pain, infection, neurologic symptoms</desc>
      <group_list>
        <group group_id="E1">
          <title>Serologic Arm</title>
          <description>Enrolled participants will have COVID19 IgG antibody testing performed.&#xD;
Serologic testing: COVID19 IgG antibody testing to be performed</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mark A. Parkulo, MD</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>9049532000</phone>
      <email>parkulo.mark@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

